Investments
2Latest ID Fund News
Oct 2, 2020
AZTherapies, Inc., a Boston, MA-based biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, closed a $33.6m Series C-1 financing.This C-1 round follows the receipt earlier this year of an additional $11.2m from the company’s previously announced Series C Preferred Stock financing, which raised aggregate gross proceeds of $37.5m.The Series C-1 round was led by Malaysia-based publicly listed pharmaceutical company and new investor Duopharma Biotech Berhad.The Series C-1 round included existing investors, led by Spinnaker Capital as well as ID Fund, DRADS Capital, and Wexford Capital, each of which also participated in the earlier Series C round.In addition, Nextrans-KCLAVIS and Axiom Associates participated as new investors in the Series C round, and DEFTA Partners as a new investor in the Series C-1 round. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
ID Fund Investments
2 Investments
ID Fund has made 2 investments. Their latest investment was in AZTherapies as part of their Series C - II on September 9, 2020.
ID Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/15/2020 | Series C - II | AZTherapies | $11.2M | Yes | 4 | |
4/30/2019 | Series A |
Date | 9/15/2020 | 4/30/2019 |
|---|---|---|
Round | Series C - II | Series A |
Company | AZTherapies | |
Amount | $11.2M | |
New? | Yes | |
Co-Investors | ||
Sources | 4 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.